Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 8/20 | 0.74 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.60 |
| ▸ | MAPK14 | Q16539 | 11/20 | 0.58 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.56 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.53 |
| ▸ | FLT1 | P17948 | 2/20 | 0.53 |
| ▸ | FLT4 | P35916 | 2/20 | 0.53 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.52 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.52 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5596350 | 0.91 | KDR (0.77) | KDRERBB2MAPK14MAPK11FGFR1 | |
| SCHEMBL5606229 | 0.90 | KDR (0.82) | KDRERBB2MAPK14MAPK11FLT1 | |
| SCHEMBL5596370 | 0.87 | KDR (0.80) | KDRERBB2MAPK14FGFR1FLT1 | |
| SCHEMBL5605872 | 0.85 | KDR (1.00) | KDRERBB2MAPK14MAPK11FLT1 | |
| SCHEMBL1227532 | 0.78 | KDR (0.81) | KDRERBB2FGFR1FLT1FLT4 | |
| SCHEMBL5596773 | 0.77 | KDR (0.79) | KDRERBB2FGFR1FLT1FLT4 | |
| SCHEMBL5606960 | 0.75 | KDR (0.80) | KDRERBB2FGFR1FLT1FLT4 | |
| SCHEMBL4405233 | 0.75 | MAPK14 (0.85) | MAPK14MAPK11 | |
| SCHEMBL5606016 | 0.75 | KDR (0.89) | KDRERBB2MAPK14FGFR1FLT1 | |
| SCHEMBL4406674 | 0.74 | MAPK14 (1.00) | MAPK14MAPK11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1543009-A4 | PYRROLOTRIAZINE KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2007-08-08 | — | — | EP | claimed |
| US-20050234060-A1 | Pyrrolotriazine kinase inhibitors | BHIDE RAJEEV S | 2005-10-20 | — | — | US | claimed |
| EP-1543009-A1 | PYRROLOTRIAZINE KINASE INHIBITORS | Bristol-Myers Squibb Company (US) | 2005-06-22 | — | — | EP | claimed |
| US-20040063708-A1 | Pyrrolotriazine kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2004-04-01 | — | — | US | claimed |
| WO-2004013145-A1 | PYRROLOTRIAZINE KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-02-12 | — | — | WO | claimed |
| US-20050234060-A1 | Pyrrolotriazine kinase inhibitors | BHIDE RAJEEV S | 2005-10-20 | — | — | US | disclosed |
| US-6951859-B2 | Pyrrolotriazine kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-10-04 | — | — | US | disclosed |
| US-20040063708-A1 | Pyrrolotriazine kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2004-04-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040063708-A1 | Pyrrolotriazine kinase inhibitors | FGFR1, FLT1, FGFR2 | KDR 7/4885ERBB2 11/4885MAPK14 332/4885 |
| US-20050234060-A1 | Pyrrolotriazine kinase inhibitors | FGFR1, FLT1, FGFR2 | KDR 7/4885ERBB2 10/4885MAPK14 350/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.